Страна: Австралия
Язык: английский
Источник: Department of Health (Therapeutic Goods Administration)
vindesine sulfate, Quantity: 5 mg
Aspen Pharmacare Australia Pty Ltd
Injection, powder for
Excipient Ingredients: mannitol
Intravenous
1 vial of powder 5mg
(S4) Prescription Only Medicine
This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code) ELDISINE is indicated in the palliative treatment of the following: Acute lymphocytic leukaemia of childhood resistant to other agents. Blastic crises of chronic myeloid leukaemia in adults. Non-small cell lung cancer. It should be noted that ELDISINE is usually given in combination with other oncolytic agents.
Visual Identification: A white to off-white lyophilised plug; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius
Licence status A
1997-08-14